Two anti-platelet drugs,Thienopyridine (clopidogrel or ticlopidine) and the platelet glycoprotein IIb/IIIainhibitor (abciximab) were conditionally recommended in coronary artery disease(CAD) patients who underwent PCI in recently updated guidelines [9], [10], [11]. The gene discussed is ART4; the disease is coronary artery disorder.